Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) dropped -0.31% by the end of trading session at $32.63. For the current quarter, the 15 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of -$0.45/share, which would compare with -$1.31 in the year-ago quarter. The net percentage change is 105.09% over the last 12 months. The trading range in the same period had a highest hit of $63.73 while lowest level was $8. At the moment the price is 5.46% above its 50-day moving average and 1.84% above its 200-day moving average.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) granted equity awards on February 28, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to four individuals hired by Sarepta in February 2017. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4).

The employees received, in the aggregate, options to purchase 7,335 shares of Sarepta’s common stock. The options have an exercise price of $31.11 per share, which is equal to the closing price of Sarepta’s common stock on February 28, 2017. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.

Cerulean Pharma Inc. (NASDAQ:CERU) last exchanged hands at a price $1.52/share, registering a gain of 8.57%. Among 2 Wall Street analysts tracked by Thomson/First Call, the average PT for CERU is $3.75 but some of them are predicting the price to move at the $6 level. If the most optimistic analysts are correct, the expected total return from the current price would be 294.74. The number of shares traded in most recent trading day was 2.06M shares which averages 1.44M shares a day. Its previous fifty two week high was $4.33 and moved down -29.95% over the same time frame, currently having a market cap around $41.62 million. Shares have risen 87.65% over the trailing six months. At the moment, the stock trades 43.46% above its 50-day moving average and 8.55% above its 200-day moving average.

Cerulean Pharma Inc. (NASDAQ:CERU) on February 1, 2017 announced that its Board of Directors is conducting a comprehensive review of strategic alternatives focused on maximizing stockholder value. Cerulean has engaged investment bank, Aquilo Partners, L.P., as its financial advisor to assist in the strategic review process.

The intention of the strategic review is to evaluate potential alternatives such as the sale of the company, a merger, a business combination, a strategic investment into the company, or a sale, license or disposition of assets of the company. This process may not result in any transaction.

In its strategic review, the Board is considering, among other things, Cerulean’s clinical assets, NDC platform, and cash reserves as outlined below:

  • Clinical assets: Cerulean’s platform-generated NDC programs, CRLX101 and CRLX301.
  • NDC Platform: Cerulean’s Dynamic Tumor Targeting™ Platform which creates NDCs that are designed to provide safer and more effective cancer treatments.
  • Cash Reserves: As of September 30, 2016, the Company had $38.1 million in cash and cash equivalents.